Elanco Animal Health, Inc.

Elanco Animal Health, Inc. specializes in providing innovative solutions for animal health, focusing on enhancing the well-being of both pets and livestock through comprehensive pharmaceuticals, vaccines, and nutritional products. Founded in 1954 and headquartered in Greenfield, US, Elanco Animal Health, Inc. is dedicated to developing health solutions for animals.

The company has evolved through strategic shifts in its offering but maintains a core focus on animal pharmaceuticals. Jeffrey Simmons currently serves as the CEO. Elanco offers a comprehensive range of innovative animal health solutions designed to enhance the wellbeing of various animals, including pets and livestock. The company’s core product offerings encompass pharmaceuticals, vaccines, and nutritional supplements aimed at addressing prevalent health challenges in animals.

These products are engineered to combat diseases, improve growth rates, and optimize overall animal health, thereby empowering veterinarians, farmers, and animal health professionals to deliver effective care. Elanco's solutions target specific issues, such as canine parvovirus in dogs and other health concerns in livestock, which are critical for maintaining productivity in agriculture. The company serves a diverse client base globally, with products marketed in North America, Europe, Asia-Pacific, and Latin America, ensuring a wide reach to both B2B and direct-to-consumer markets. Elanco generated a revenue of USD 4,439 mn for the year 2024, while reporting an EBITDA loss of USD 224 mn for 2023.

The company’s revenue model is supported by its flagship products, which include vaccines and targeted therapeutics, driving a steady stream of transactions within the animal health sector. Transactions typically occur on a B2B basis, where retailers and veterinary clinics purchase products for resale to end consumers, ensuring consistent availability of essential animal health solutions.